Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss

J. Sibonga, T. Matsumoto, J. Jones, Jay Shapiro, T. Lang, L. Shackelford, S. M. Smith, M. Young, J. Keyak, K. Kohri, H. Ohshima, E. Spector, A. LeBlanc

Research output: Contribution to journalArticle

Abstract

Bone loss in astronauts during spaceflight may be a risk factor for osteoporosis, fractures and renal stone formation. We previously reported that the bisphosphonate alendronate, combined with exercise that included an Advanced Resistive Exercise Device (ARED), can prevent or attenuate group mean declines in areal bone mineral density (aBMD) measured soon after ~ 6-month spaceflights aboard the International Space Station (ISS). It is unclear however if the beneficial effects on postflight aBMD were due to individual or combined effects of alendronate and ARED. Hence, 10 additional ISS astronauts were recruited who used the ARED (ARED group) without drug administration using similar measurements in the previous study, i.e., densitometry, biochemical assays and analysis of finite element (FE) models. In addition densitometry data (DXA and QCT only) were compared to published data from crewmembers (n = 14–18) flown prior to in-flight access to the ARED (Pre-ARED). Group mean changes from preflight (± SD %) were used to evaluate effects of countermeasures as sequentially modified on the ISS (i.e., Pre-ARED vs. ARED; ARED vs. Bis+ARED). Spaceflight durations were not significantly different between groups. Postflight bone density measurements were significantly reduced from preflight in the Pre-ARED group. As previously reported, combined Bis+ARED prevented declines in all DXA and QCT hip densitometry and in estimates of FE hip strengths; increased the aBMD of lumbar spine; and prevented elevations in urinary markers for bone resorption during spaceflight. ARED without alendronate partially attenuated declines in bone mass but did not suppress biomarkers for bone resorption or prevent trabecular bone loss. Resistive exercise in the ARED group did not prevent declines in hip trabecular vBMD, but prevented reductions in cortical vBMD of the femoral neck, in FE estimate of hip strength for non-linear stance (NLS) and in aBMD of the femoral neck. We conclude that a bisphosphonate, when combined with resistive exercise, enhances the preservation of bone mass because of the added suppression of bone resorption in trabecular bone compartment not evident with ARED alone.

Original languageEnglish (US)
Article number112037
JournalBone
Volume128
DOIs
StatePublished - Nov 1 2019

Fingerprint

Astronauts
Space Flight
Exercise
Bone and Bones
Equipment and Supplies
Bone Density
Alendronate
Densitometry
Hip
Bone Resorption
Femur Neck
Diphosphonates
Finite Element Analysis

Keywords

  • Alendronate
  • Bone
  • Densitometry
  • Finite element modeling
  • Hip fracture
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. / Sibonga, J.; Matsumoto, T.; Jones, J.; Shapiro, Jay; Lang, T.; Shackelford, L.; Smith, S. M.; Young, M.; Keyak, J.; Kohri, K.; Ohshima, H.; Spector, E.; LeBlanc, A.

In: Bone, Vol. 128, 112037, 01.11.2019.

Research output: Contribution to journalArticle

Sibonga, J, Matsumoto, T, Jones, J, Shapiro, J, Lang, T, Shackelford, L, Smith, SM, Young, M, Keyak, J, Kohri, K, Ohshima, H, Spector, E & LeBlanc, A 2019, 'Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss', Bone, vol. 128, 112037. https://doi.org/10.1016/j.bone.2019.07.013
Sibonga, J. ; Matsumoto, T. ; Jones, J. ; Shapiro, Jay ; Lang, T. ; Shackelford, L. ; Smith, S. M. ; Young, M. ; Keyak, J. ; Kohri, K. ; Ohshima, H. ; Spector, E. ; LeBlanc, A. / Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss. In: Bone. 2019 ; Vol. 128.
@article{6ee2e8a5f584419b9c4bcd6bb3528546,
title = "Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss",
abstract = "Bone loss in astronauts during spaceflight may be a risk factor for osteoporosis, fractures and renal stone formation. We previously reported that the bisphosphonate alendronate, combined with exercise that included an Advanced Resistive Exercise Device (ARED), can prevent or attenuate group mean declines in areal bone mineral density (aBMD) measured soon after ~ 6-month spaceflights aboard the International Space Station (ISS). It is unclear however if the beneficial effects on postflight aBMD were due to individual or combined effects of alendronate and ARED. Hence, 10 additional ISS astronauts were recruited who used the ARED (ARED group) without drug administration using similar measurements in the previous study, i.e., densitometry, biochemical assays and analysis of finite element (FE) models. In addition densitometry data (DXA and QCT only) were compared to published data from crewmembers (n = 14–18) flown prior to in-flight access to the ARED (Pre-ARED). Group mean changes from preflight (± SD {\%}) were used to evaluate effects of countermeasures as sequentially modified on the ISS (i.e., Pre-ARED vs. ARED; ARED vs. Bis+ARED). Spaceflight durations were not significantly different between groups. Postflight bone density measurements were significantly reduced from preflight in the Pre-ARED group. As previously reported, combined Bis+ARED prevented declines in all DXA and QCT hip densitometry and in estimates of FE hip strengths; increased the aBMD of lumbar spine; and prevented elevations in urinary markers for bone resorption during spaceflight. ARED without alendronate partially attenuated declines in bone mass but did not suppress biomarkers for bone resorption or prevent trabecular bone loss. Resistive exercise in the ARED group did not prevent declines in hip trabecular vBMD, but prevented reductions in cortical vBMD of the femoral neck, in FE estimate of hip strength for non-linear stance (NLS) and in aBMD of the femoral neck. We conclude that a bisphosphonate, when combined with resistive exercise, enhances the preservation of bone mass because of the added suppression of bone resorption in trabecular bone compartment not evident with ARED alone.",
keywords = "Alendronate, Bone, Densitometry, Finite element modeling, Hip fracture, Osteoporosis",
author = "J. Sibonga and T. Matsumoto and J. Jones and Jay Shapiro and T. Lang and L. Shackelford and Smith, {S. M.} and M. Young and J. Keyak and K. Kohri and H. Ohshima and E. Spector and A. LeBlanc",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.bone.2019.07.013",
language = "English (US)",
volume = "128",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Resistive exercise in astronauts on prolonged spaceflights provides partial protection against spaceflight-induced bone loss

AU - Sibonga, J.

AU - Matsumoto, T.

AU - Jones, J.

AU - Shapiro, Jay

AU - Lang, T.

AU - Shackelford, L.

AU - Smith, S. M.

AU - Young, M.

AU - Keyak, J.

AU - Kohri, K.

AU - Ohshima, H.

AU - Spector, E.

AU - LeBlanc, A.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Bone loss in astronauts during spaceflight may be a risk factor for osteoporosis, fractures and renal stone formation. We previously reported that the bisphosphonate alendronate, combined with exercise that included an Advanced Resistive Exercise Device (ARED), can prevent or attenuate group mean declines in areal bone mineral density (aBMD) measured soon after ~ 6-month spaceflights aboard the International Space Station (ISS). It is unclear however if the beneficial effects on postflight aBMD were due to individual or combined effects of alendronate and ARED. Hence, 10 additional ISS astronauts were recruited who used the ARED (ARED group) without drug administration using similar measurements in the previous study, i.e., densitometry, biochemical assays and analysis of finite element (FE) models. In addition densitometry data (DXA and QCT only) were compared to published data from crewmembers (n = 14–18) flown prior to in-flight access to the ARED (Pre-ARED). Group mean changes from preflight (± SD %) were used to evaluate effects of countermeasures as sequentially modified on the ISS (i.e., Pre-ARED vs. ARED; ARED vs. Bis+ARED). Spaceflight durations were not significantly different between groups. Postflight bone density measurements were significantly reduced from preflight in the Pre-ARED group. As previously reported, combined Bis+ARED prevented declines in all DXA and QCT hip densitometry and in estimates of FE hip strengths; increased the aBMD of lumbar spine; and prevented elevations in urinary markers for bone resorption during spaceflight. ARED without alendronate partially attenuated declines in bone mass but did not suppress biomarkers for bone resorption or prevent trabecular bone loss. Resistive exercise in the ARED group did not prevent declines in hip trabecular vBMD, but prevented reductions in cortical vBMD of the femoral neck, in FE estimate of hip strength for non-linear stance (NLS) and in aBMD of the femoral neck. We conclude that a bisphosphonate, when combined with resistive exercise, enhances the preservation of bone mass because of the added suppression of bone resorption in trabecular bone compartment not evident with ARED alone.

AB - Bone loss in astronauts during spaceflight may be a risk factor for osteoporosis, fractures and renal stone formation. We previously reported that the bisphosphonate alendronate, combined with exercise that included an Advanced Resistive Exercise Device (ARED), can prevent or attenuate group mean declines in areal bone mineral density (aBMD) measured soon after ~ 6-month spaceflights aboard the International Space Station (ISS). It is unclear however if the beneficial effects on postflight aBMD were due to individual or combined effects of alendronate and ARED. Hence, 10 additional ISS astronauts were recruited who used the ARED (ARED group) without drug administration using similar measurements in the previous study, i.e., densitometry, biochemical assays and analysis of finite element (FE) models. In addition densitometry data (DXA and QCT only) were compared to published data from crewmembers (n = 14–18) flown prior to in-flight access to the ARED (Pre-ARED). Group mean changes from preflight (± SD %) were used to evaluate effects of countermeasures as sequentially modified on the ISS (i.e., Pre-ARED vs. ARED; ARED vs. Bis+ARED). Spaceflight durations were not significantly different between groups. Postflight bone density measurements were significantly reduced from preflight in the Pre-ARED group. As previously reported, combined Bis+ARED prevented declines in all DXA and QCT hip densitometry and in estimates of FE hip strengths; increased the aBMD of lumbar spine; and prevented elevations in urinary markers for bone resorption during spaceflight. ARED without alendronate partially attenuated declines in bone mass but did not suppress biomarkers for bone resorption or prevent trabecular bone loss. Resistive exercise in the ARED group did not prevent declines in hip trabecular vBMD, but prevented reductions in cortical vBMD of the femoral neck, in FE estimate of hip strength for non-linear stance (NLS) and in aBMD of the femoral neck. We conclude that a bisphosphonate, when combined with resistive exercise, enhances the preservation of bone mass because of the added suppression of bone resorption in trabecular bone compartment not evident with ARED alone.

KW - Alendronate

KW - Bone

KW - Densitometry

KW - Finite element modeling

KW - Hip fracture

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=85070884331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070884331&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2019.07.013

DO - 10.1016/j.bone.2019.07.013

M3 - Article

C2 - 31400472

AN - SCOPUS:85070884331

VL - 128

JO - Bone

JF - Bone

SN - 8756-3282

M1 - 112037

ER -